US government assessments of active pharmaceutical ingredient sourcing highlight vulnerabilities in concentrated manufacturing locations. Primary documents such as the 2021 Executive Order on America's Supply Chains direct federal agencies to review critical sector dependencies, including pharmaceuticals, without prescribing specific production locations. Industry analyses note that cost structures and regulatory timelines influence decisions on facility siting across multiple countries. Chinese five-year planning documents emphasize biotechnology targets, while US legislative measures including tax provisions for immediate expensing of research costs aim to support domestic capacity expansion. Puerto Rico manufacturing investments referenced in congressional records illustrate existing regional hubs. Perspectives from supply chain resilience reports contrast centralized industrial strategies with market-driven allocation of capital. Data from FDA drug shortage notifications and import statistics provide baseline metrics on sourcing origins, though exact shares vary by therapeutic category. Connections to broader trade measures, such as those involving rare earth elements, appear in Commerce Department reviews but differ in enforcement mechanisms from pharmaceutical inputs. Policy continuity across administrations remains subject to legislative codification rather than executive directives alone.